1. Errata : ocena kadrovskih potreb za izvajanje zdravljenja raka v Republiki SlovenijiKatarina Lokar, Marjana Bernot, Maja Ebert Moltara, Mateja Marc-Malovrh, Radivoje Pribaković Brinovec, Brigita Skela-Savič, Vesna Zadnik, Tina Žagar, Branko Zakotnik, 2021, drugi sestavni deli Ključne besede: načrtovanje zdravstvenega osebja, zdravljenje raka, paliativna oskrba, incidenca, umrljivost, napovedovanje
Objavljeno v DiRROS: 22.01.2026; Ogledov: 171; Prenosov: 93
 Celotno besedilo (333,54 KB)
Gradivo ima več datotek! Več... |
2. Poročilo Državnega programa obvladovanja raka za leto 2024Sonja Tomšič, Janez Žgajnar, Katarina Plantosar, Amela Duratović Konjević, Joka Kosmina, Branko Zakotnik, 2025, objavljeni strokovni prispevek na konferenci Ključne besede: javno zdravje, preventivni programi, onkologija
Objavljeno v DiRROS: 11.09.2025; Ogledov: 442; Prenosov: 156
Celotno besedilo (89,21 KB) |
3. Votrient (pazopanib) : spremljevalni vodnik za zdravljenjeBreda Škrbinc, 2013, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Ključne besede: rak ledvic, tarčna zdravila, bolniki, onkološki bolniki, vodniki
Objavljeno v DiRROS: 03.09.2025; Ogledov: 365; Prenosov: 105
 Povezava na datoteko |
4. Timski pristop k zdravljenju raka glave in vratuPrimož Strojan, Cvetka Grašič-Kuhar, Branko Zakotnik, 2025, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Ključne besede: timska obravnava, stranski učinki, bolniki, zdravstveni nasveti
Objavljeno v DiRROS: 07.08.2025; Ogledov: 477; Prenosov: 157
Celotno besedilo (1,04 MB) |
5. |
6. Trends in population-based cancer survival in SloveniaVesna Zadnik, Tina Žagar, Katarina Lokar, Sonja Tomšič, Amela Duratović Konjević, Branko Zakotnik, 2021, izvirni znanstveni članek Ključne besede: cancer burden, cancer survival, time trend, cancer registry
Objavljeno v DiRROS: 22.07.2024; Ogledov: 956; Prenosov: 601
Celotno besedilo (693,86 KB)
Gradivo ima več datotek! Več... |
7. Poročilo državnega programa obvladovanja raka za leto 2023Sonja Tomšič, Janez Žgajnar, Katarina Plantosar, Amela Duratović Konjević, Katarina Torkar, Branko Zakotnik, 2024, objavljeni strokovni prispevek na konferenci Ključne besede: obvladovanje raka, državni program, onkologija
Objavljeno v DiRROS: 06.06.2024; Ogledov: 1035; Prenosov: 342
Celotno besedilo (66,82 KB) |
8. Prognostic value of some tumor markers in unresectable stage IV oropharyngeal carcinoma patients treated with concomitant radiochemotherapyErika Šoba, Marjan Budihna, Alojz Šmid, Nina Gale, Hotimir Lešničar, Branko Zakotnik, Primož Strojan, 2015, izvirni znanstveni članek Povzetek: The aim of the study was to investigate how the expression of tumor markers p21, p27, p53, cyclin D1, EGFR, Ki-67, and CD31 influenced the outcome of advanced inoperable oropharyngeal carcinoma patients, treated with concomitant radiochemotherapy. Patients and methods. The pretreatment biopsy specimens of 74 consecutive patients with inoperable stage IV oropharyngeal squamous cell carcinoma treated with concomitant radiochemotherapy were in retrospective study processed by immunochemistry for p21, p27, p53, cyclin D1, EGFR, Ki-67, and CD31. Disease-free survival (DFS) was assessed according to the expression of tumor markers. Results. Patients with a high expression of p21 (%10%), p27 (>50%), Ki-67 (>50%), CD31 (>130 vessels/mm2) and low expression of p53 (<10%), cyclin D1 (<10%) and EGFR (<10%) (favorable levels - FL) had better DFS than patients with a low expression of p21 (<10%), p27 (%50%), Ki-67 (%50%), CD31 (<130 vessels/mm2) and high expression of p53 (%10%), cyclin D1 (%10%) and EGFR (%10%) (unfavorable levels - UL). However, statistical significance in survival between FL and UL was achieved only for p27 and cyclin D1. DFS significantly decreased with an increasing number of markers with an unfavorable level per tumor (1%4 vs. 5%7) (78% vs. 32%, respectively; p = 0.004). The number of markers per tumor with UL of expression retained prognostic significance also in multivariate analysis. Conclusions. Statistical significance in survival between FL and UL emerged only for p27 and cyclin D1. The number of markers per tumor with UL of expression was an independent prognostic factor for an adverse outcome .
Ključne besede: oropharynx, radiochemotherapy, tumor markers
Objavljeno v DiRROS: 22.04.2024; Ogledov: 1373; Prenosov: 424
Celotno besedilo (560,05 KB) |
9. Effectiveness of adjuvant trastuzumab in daily clinical practiceErika Matos, Branko Zakotnik, Cvetka Grašič-Kuhar, 2014, izvirni znanstveni članek Povzetek: Background. Human epidermal growth factor receptor 2 (HER2) positive breast cancer is an entity with aggressive behaviour. One year of adjuvant trastuzumab significantly improves the disease free survival in the range of 40-50% and reduces the risk of dying from HER2 positive breast cancer by one third. Adjuvant treatment with trastuzumab became available in Slovenia in 2005 and the aim of this study is to explore, if the exceptional results reported in adjuvant clinical trials are achieved also in daily clinical practice. Patients and methods. An analysis of tumour and patient characteristics, type of treatment and outcome (relapse free and overall survival) of 313 patients (median age 52 years) treated at the Institute of Oncology Ljubljana in years 2005-2009 was performed. Results. Median follow-up was 4.4 years. Sixty-one patients relapsed and 24 died. Three and four years relapse free survival was 84.2% and 80.8% and the overall survival was 94.4% and 92.5%, respectively. Independent prognostic factors for relapse were tumour grade (HR 2.10; 95% CI 1.07-4.14; p = 0.031) and nodal stage (HR 1.35; 1.16-1.56; p < 0.0001) and for the overall survival nodal stage only (HR 1.36; 1.05-1.78; p = 0.021). Conclusions. The outcome in patients with adjuvant trastuzumab in daily clinical practice, treated by medical oncologists, is comparable to results obtained in international adjuvant studies.
Ključne besede: breast cancer, trastuzumab, adjuvant, clinical practice
Objavljeno v DiRROS: 11.04.2024; Ogledov: 1433; Prenosov: 624
Celotno besedilo (549,44 KB) |
10. |
